On a mission
to cure neurodegenerative disease
and delay brain aging
APPROACH
Unlocking nature’s blueprint for resilience
Our platform identifies naturally occuring gene variants that protect against neurodegeneration. Using machine learning to mine large-scale genomic and clinical datasets, we identify and prioritize gene variants with the strongest protective effects and rapidly design oligonucleotide therapeutics mimicking their effect.
De-risked by human genetics
By mimicking protective mechanisms found in resilient individuals, we target genetically validated pathways already shown to slow or prevent disease in the human population. This reduces reliance on hypothetical biologic mechanisms, validation bias from cell and animal disease models, and ultimately minimizes translational risk.
Broad impact beyond rare mutations
Unlike therapies aimed only at rare genetic subtypes, we address shared drivers of both familial and sporadic forms of ALS, FTD, and other neurodegenerative diseases, often related to neuroinflammation. This strategy dramatically expands both the patient population and commercial potential.
CORE TEAM
-
Martin Jacko, Ph.D.
FOUNDER & CEO
-
Therése Dalebrant, M.Sc.
CHIEF OF STAFF
-
Dario Tejera, Ph.D.
PRINCIPAL SCIENTIST
-
Andreia Goncalves, Ph.D.
R&D STRATEGY & OPS MANAGER
-
Arventh Velusamy, Ph.D.
SCIENTIST II
ADVISORY BOARD
-
Hynek Wichterle, Ph.D.
PROFESSOR, COLUMBIA UNIVERSITY
-
John Dunlop, Ph.D.
BOARD MEMBER, TARGET ALS
-
Michael Heneka, M.D.
DIRECTOR, LUXEMBOURG CENTRE FOR SYSTEMS BIOSCIENCE
-
Ryan Corces, Ph.D.
ASSISTANT PROFESSOR, GLADSTONE INSTITUTES & UCSF
-
Amit Deshwar, Ph.D.
CO-FOUNDER & CTO, KERNA LABS
